# Amit M. Oza

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/amit-m-oza/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,463 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 103 |
| i10-index | 449 |
| Last Known Institution | Ontario Institute for Cancer Research |
| OpenAlex ID | https://openalex.org/A5072712459 |
| ORCID iD | 0000-0002-9510-8641 |
| Works | 1,226 |

## Researcher papers

Showing 12 of 28.

- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Epithelial ovarian cancer](https://scholariq.org/papers/epithelial-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial](https://scholariq.org/papers/early-palliative-care-for-patients-with-advanced-cancer-a-cluster-randomised/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Rethinking ovarian cancer: recommendations for improving outcomes](https://scholariq.org/papers/rethinking-ovarian-cancer-recommendations-for-improving-outcomes/)
- [Epithelial ovarian cancer: Evolution of management in the era of precision medicine](https://scholariq.org/papers/epithelial-ovarian-cancer-evolution-of-management-in-the-era-of-precision/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial](https://scholariq.org/papers/standard-chemotherapy-with-or-without-bevacizumab-for-women-with-newly-diagnosed/)
- [Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial](https://scholariq.org/papers/olaparib-combined-with-chemotherapy-for-recurrent-platinum-sensitive-ovarian/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

## Researcher university

- [Ontario Institute for Cancer Research](https://scholariq.org/institutions/ontario-institute-for-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.